JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

132.5

-1.62%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Avatud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	6.8M -8.1M
Müük	33M 72M
Aktsiakasum	-0.04
Kasumimarginaal	-11.242
Töötajad	105
EBITDA	6.7M -5.4M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. märts 2026

Turustatistika
By TradingEconomics
Turukapital	67M 158M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. jaan 2026, 23:51 UTC

Tulu

Correction to Samsung Fourth-Quarter Net Profit Article

28. jaan 2026, 23:49 UTC

Kuumad aktsiad

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28. jaan 2026, 23:19 UTC

Tulu

Samsung's Fourth-Quarter Net Profit Beats Consensus

28. jaan 2026, 22:43 UTC

Tulu

Waste Management Logs Higher 4Q Profit as Revenue Rises

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28. jaan 2026, 23:49 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28. jaan 2026, 23:30 UTC

Market Talk

Tesla to Use Car Factory for Robot Aims -- Market Talk

28. jaan 2026, 23:28 UTC

Tulu

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28. jaan 2026, 23:26 UTC

Tulu

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28. jaan 2026, 23:21 UTC

Tulu

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28. jaan 2026, 23:18 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28. jaan 2026, 22:58 UTC

Tulu

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28. jaan 2026, 22:48 UTC

Market Talk

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28. jaan 2026, 22:45 UTC

Tulu

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28. jaan 2026, 22:44 UTC

Tulu

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28. jaan 2026, 22:43 UTC

Tulu

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28. jaan 2026, 22:41 UTC

Tulu

Kuumad aktsiad

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28. jaan 2026, 22:41 UTC

Market Talk

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28. jaan 2026, 22:41 UTC

Tulu

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28. jaan 2026, 22:40 UTC

Tulu

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28. jaan 2026, 22:39 UTC

Tulu

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28. jaan 2026, 22:38 UTC

Tulu

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28. jaan 2026, 22:37 UTC

Tulu

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28. jaan 2026, 22:35 UTC

Tulu

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28. jaan 2026, 22:26 UTC

Market Talk

Tulu

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28. jaan 2026, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

28. jaan 2026, 22:20 UTC

Market Talk

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.